Dissimilar tumor cell populations in ascitic fluid of ovarian cancer patients

Кайгородова, Е. В.; Fedulova, N.; Очиров, М. О.; Дьяков, Д. А.; Molchanov, Sergey V.; Часовских, Н. Ю.

doi:10.20538/1682-0363-2020-1-50-58

Cited by 7 publications

(6 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These cells express CD45, which is common for every human leukocyte [ 55 ], EpCAM (epithelial cell adhesion molecule), which is found in most epithelial cancer cells [ 56 ], and cytokeratins [ 57 ]. Kaigorodova et al (2020) [ 58 ] identified 12 different populations of cancer cells in the ascites fluid from ovarian cancer patients. The authors found that the majority of cells were represented by atypical cells with hybrid phenotype, stemness, and evidences of EMT (EpCAM + , CD45 + , CD44 + , CD24 +/– , CD133 +/– , N-cadherin +/– ).…”

Section: Characteristic Of Hybrid Cancer Cellsmentioning

confidence: 99%

Hybrid/Atypical Forms of Circulating Tumor Cells: Current State of the Art

Кайгородова

Kozik

Zavaruev

et al. 2022

Biochemistry Moscow

View full text Add to dashboard Cite

Cancer is one of the most common diseases worldwide, and its treatment is associated with many challenges such as drug and radioresistance and formation of metastases. These difficulties are due to tumor heterogeneity, which has many causes. One may be the cell fusion, a process that is relevant to both physiological (e.g., wound healing) and pathophysiological (cancer and viral infection) processes. This literature review aimed to summarize the existing data on the hybrid/atypical forms of circulating cancer cells and their role in tumor progression. For that, the bioinformatics search in universal databases, such as PubMed, NCBI, and Google Scholar was conducted by using the keywords “hybrid cancer cells”, “cancer cell fusion”, etc. In this review the latest information related to the hybrid tumor cells, theories of their genesis, characteristics of different variants with data from our own researches are presented. Many aspects of the hybrid cell research are still in their infancy. However, with the level of knowledge already accumulated, circulating hybrids such as CAML and CHC could be considered as promising biomarkers of cancerous tumors, and even more as a new approach to cancer treatment.

show abstract

Section: Characteristic Of Hybrid Cancer Cellsmentioning

confidence: 99%

Hybrid/Atypical Forms of Circulating Tumor Cells: Current State of the Art

Кайгородова

Kozik

Zavaruev

et al. 2022

Biochemistry Moscow

View full text Add to dashboard Cite

show abstract

“…Асцитическая жидкость является перспективным биологическим материалом для получения информации о характере опухолевого процесса при РЯ. Недавние исследования показали, что клетки асцитической жидкости больных РЯ представляют собой гетерогенную популяцию, в состав которой входят стволовые опухолевые клетки [8]. Известно, что маркерами стволовых опухолевых клеток РЯ являются CD44, CD24, CD133, CD117 [9].…”

Section: клинический случайunclassified

“…Клеточный состав асцитической жидкости больных РЯ представляет собой гетерогенную популяцию. Большую концентрацию асцитических опухолевых клеток представляют собой атипичные / гибридные формы опухолевых клеток с признаком стволовости, а также стволовые опухолевые клетки EpCAM+CD45-CD44+CD24+CD133± как с признаком ЕМТ (epithelialmesenchymal transition), так и без него [8]. Также показано, что количество асцитических клеток с фенотипом EpCAM+CD45-CD44-CD24+CD133-N-cadherin+ и атипичных / гибридных форм клеток EpCAM+CD45+CD44+-CD24±CD133±N-cad herin± в асцитической жидкости прямо коррелирует со степенью канцероматоза [12].…”

Section: клинический случайunclassified

Heterogeneity of EpCAM-positive cells in low-grade serous ovarian carcinoma ascitic fluid: a clinical case

Кайгородова

Kovalev

Чернышова

et al. 2022

Opuholi ženskoj reproduktivnoj sistemy

Self Cite

View full text Add to dashboard Cite

Ovarian cancer is one of the most malignant and aggressive tumors of the female reproductive system. Late diagnosis is one of the most significant problems: more than two-thirds of cases are detected only at stage III–IV. Ovarian cancer is characterized by a unique metastatic process. Implantation is the earliest and most common way of metastasis. It is often accompanied by fluid accumulation in the abdominal cavity, known as ascites. We report a case of low-grade serous ovarian carcinoma with a large heterogeneity of tumor cells in the ascitic fluid detected using multicolor flow cytometry. We demonstrated the advantages and benefits of this method in the diagnosis of ovarian cancer. Multicolor flow cytometry opens new horizons for liquid biopsy in oncology.

show abstract

“…Значительный интерес среди злокачественных клеток, определяемых в асцитической жидкости, вызывает недавно открытая группа атипичных/гибридных клеток, образующихся в результате слияния раковой клетки и лейкоцитов. Такие клетки экспрессируют маркер CD45, характерный для всех видов лейкоцитов человека [3] и EpCAM -молекулу клеточной адгезии эпителия, обнаруживающуюся у большинства раковых эпителиальных клеток [4,5] и в 70 % случаев рака яичников [6,7].…”

unclassified

EPCAM+CD45+ cells in ascitic fluid of patients with ovarian cancer: a relationship with tumor marker levels and tumor grade

et al. 2022

Self Cite

View full text Add to dashboard Cite

Purpose of the study: to assess the relationship between atypical/hybrid forms of EpCAM+CD45+ cells in ascitic fluid of ovarian cancer patients and the levels of cancer markers, such as CA125 and HE4, and the tumor grade. Material and methods. The study included 48 patients with newly diagnosed ovarian cancer (42 patients with stage Ic–IV ovarian cancer and 6 patients with borderline ovarian tumors (Bots). The age of the patients ranged from 36 to 76 years. the study material included ascitic fluid and blood samples. the presence of atypical/hybrid forms of EpCAM+CD45+ cells in ascitic fluid was identified by laser multicolor flow cytometry. The levels of CA125 and HE4 markers were measured by ELISA. Results. The number of EpCAM+CD45+ cells in ascitic fluid of patients with serous ovarian carcinoma was 1.02 (0.30; 2.68) cells/µl (0.55 (0.03; 4.51) cells/µl in patients with low-grade serous carcinoma (LGSC) and 1.36 (0.41; 2.68) cells/µl in patients with high-grade serous carcinoma (HGSC). The number of EpCAM+CD45+ cells in ascitic fluid of serous ovarian carcinoma was shown to have a strong correlation with СА125 and HE4 levels in blood serum (R=0.60; р<0.01 and R=0.34; р=0.05, respectively). In the LGSC group, there was a strong direct correlation between the number of EpCAM+CD45+ cells in ascitic fluid and the levels of CA125 and HE4 markers in blood serum (R=0.93; p<0.01 and R=0.68; p=0.03, respectively). No differences in the levels of EpCAM+CD45+ cells in ascitic fluid and CA125/ HE4 markers in blood serum between patients with HGSC and LGSC were found. the levels of atypical/hybrid forms of cells in ascitic fluid and CA125/ HE4 markers in blood serum were significantly lower in patients with Bots than in patients with serous ovarian carcinoma (p=0.02 for EpCAM+CD45+ cells and p<0.01 for СА125/ HE4 levels). Conclusion. The relationship between the number of EpCAM+CD45+ cells in ascitic fluid and the levels of CA125 and HE4 markers in blood serum of patients with serous ovarian carcinoma was found. However, no differences in the levels of EpCAM+CD45+ cells in ascitic fluid and CA125/ HE4 markersin blood serum between patients with HGSC and LGSC were observed.

show abstract

Dissimilar tumor cell populations in ascitic fluid of ovarian cancer patients

Cited by 7 publications

References 13 publications

Hybrid/Atypical Forms of Circulating Tumor Cells: Current State of the Art

Hybrid/Atypical Forms of Circulating Tumor Cells: Current State of the Art

Heterogeneity of EpCAM-positive cells in low-grade serous ovarian carcinoma ascitic fluid: a clinical case

EPCAM+CD45+ cells in ascitic fluid of patients with ovarian cancer: a relationship with tumor marker levels and tumor grade

Contact Info

Product

Resources

About